Cap­ping a tur­bu­lent saga around Alzheimer's drug, Cor­texyme strikes a deal, brings in new man­age­ment and changes name in search of new life

A failed at­tempt to bring for­ward an un­ortho­dox ap­proach to treat­ing Alzheimer’s dis­ease has cul­mi­nat­ed in the com­plete re­make of Cor­texyme.

The trou­bled pub­lic biotech $CRTX says it’s struck a deal to ac­quire a pri­vate start­up called Novos­teo, which is fo­cused on rare skele­tal dis­eases, bone can­cer and in­jury. Novos­teo CEO Dirk Thye and CMO Karen Smith will be run­ning things from here on out in those ex­act same roles, while Cor­texyme changes its name to Quince Ther­a­peu­tics over the com­ing months.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER